Research Update

ReNeuron Group plc
23 April 2008


   ReNeuron announces further pre-clinical data with its ReN003 programme for
                             diseases of the retina


Guildford, UK, 23 April 2008: ReNeuron Group plc (LSE: RENE.L) today announces
further pre-clinical data regarding its ReN003 stem cell therapy programme for
diseases of the retina.

The research was conducted by Dr Michael Young's team at the Schepens Eye
Research Institute at Harvard Medical School, Boston, US.  ReNeuron's ReN003
human retinal progenitor cells were tested in a rodent model of damaged retina.
Between 14 and 28 days after transplantation into the sub-retinal space, the
cells were seen to integrate with the host retinal tissue.  A sub-population of
these integrated cells differentiated into cells exhibiting the characteristics
of photoreceptors, expressing the proteins rhodopsin and recoverin, markers for
the light-sensitive rod cells found in healthy retina.

These results therefore indicate the potential utility of ReNeuron's prototype
ReN003 cell line as a therapy for blindness-causing diseases characterised by
damage to the retina, such as retinitis pigmentosa, age-related macular
degeneration and diabetic retinopathy.  The results will be presented by Dr
Young at the Annual Meeting of the Association for Research in Vision and
Ophthalmology (ARVO) in Fort Lauderdale, Florida on 27 April to 1 May, 2008.1


Dr John Sinden, Chief Scientific Officer of ReNeuron, said:

'We are greatly encouraged by these new results generated by Mike Young and his
team at Schepens using our prototype ReN003 retinal cell line.  There is still
much work to do before this cell line can be taken into the clinic, but these
early pre-clinical results give us the confidence to move the programme in that
direction as quickly as possible.'


Dr Young commented:

'We are very excited about the potential these cells hold for the treatment of
retinal degeneration.'


1.  Programme /poster 3571/D724: SG Schmitt, U Aftab, C Jiang, B Tucker, L
Stevanato, E Miljan, J Sinden, H Klassen, M Young


Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer                    Tel: [phone]
Dr John Sinden, Chief Scientific Officer


Financial Dynamics
Europe
David Yates                                             Tel: [phone]
Lara Mott
US
Robert Stanislaro                                       Tel : [phone]


Collins Stewart
Tim Mickley                                             Tel: [phone]



About ReNeuron

ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.  The
Company operates from laboratories in Surrey, UK and Los Angeles, California,
USA.

ReNeuron has used its proprietary, patented cell expansion technology to
generate genetically stable neural stem cell lines.  This technology platform
has multi-national patent protection and is fully regulated by means of a
chemically-induced safety switch.  Cell growth can therefore be completely
arrested prior to in vivo implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  In
addition to its stroke programme, ReNeuron is developing stem cell therapies for
Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of the
retina.  The Company recently acquired the business assets of AmCyte Inc. in the
US, bringing clinically-tested cell encapsulation technology to ReNeuron's
ReN002 diabetes programme.

ReNeuron has leveraged its stem cell technologies into non-therapeutic areas -
its ReNcell(R) range of cell lines for use in research and in drug discovery
applications in the pharmaceutical industry.  ReNeuron's ReNcell(R)CX and
ReNcell(R)VM neural cell lines are marketed worldwide under license by Millipore
Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
Further information on ReNeuron and its products can be found at
www.reneuron.com.


About the Schepens Eye Research Institute

Schepens Eye Research Institute fights blindness by developing new technologies,
therapies and knowledge to preserve and restore vision. Through a continuum of
discovery, the Institute works toward a future in which blindness is prevented,
alleviated, and, ultimately, cured.

Founded in 1950 by famed retinal surgeon Charles L. Schepens, M.D., Schepens Eye
Research Institute is the largest independent eye research institute in the
United States and an affiliate of Harvard Medical School. Since its inception,
the Institute has trained more than 600 postdoctoral fellows in various
disciplines of eye research; trained more than 500 eye surgeons who now practice
around the world; and published more than 4,600 scientific papers and books
about health and eye disease.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange